消炎利胆片联合头孢哌酮舒巴坦对急性胆囊炎患者炎性因子指标的影响
Impact of Xiaoyan Lidan Tablets Combined with Cefoperazone Sulbactam on Inflammatory Factor Indicators in Patients with Acute Cholecystitis
饶丽婷 1王会燕1
作者信息
- 1. 抚州市东乡区人民医院药剂科,江西抚州 331800
- 折叠
摘要
目的 探讨消炎利胆片联合头孢哌酮舒巴坦对急性胆囊炎患者炎性因子指标的影响.方法 选取 2020 年 1 月至 2022年 12 月我院收治急性胆囊炎患者 70 例,随机分为两组各 35 例.对照组采用头孢哌酮舒巴坦治疗,观察组在对照组基础上采用消炎利胆片治疗,两组均持续治疗 1 个月.比较两组的临床疗效、炎性因子指标及不良反应发生率.结果 观察组治疗总有效率高于对照组(P＜0.05).治疗后,观察组IL-6、CRP、TNF-α水平低于对照组(P＜0.05).两组的不良反应发生率比较差异无统计学意义(P＞0.05).结论 消炎利胆片联合头孢哌酮舒巴坦治疗急性胆囊炎患者的效果显著,可改善患者炎性反应状态,且无明显不良反应,临床应用安全性高.
Abstract
Objective To explore the impact of Xiaoyan Lidan tablets combined with cefoperazone sulbactam on inflammatory factor indicators in patients with acute cholecystitis.Methods 70 patients with acute cholecystitis admitted to our hospital from January 2020 to December 2022 were selected and randomly divided into two groups,with 35 cases in each group.The control group was treated with cefoperazone sulbactam,while the observation group was treated with Xiaoyan Lidan tablets on the basis of the control group.Both groups were treated for 1 month continuously.The clinical efficacy,inflammatory factor indicators,and incidence of adverse reactions were compared between two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the IL-6,CRP and TNF-α levels of the observation group were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Xiaoyan Lidan tablets combined with cefoperazone sulbactam has significant effect in the treatment of patients with acute cholecystitis,and can improve the inflammatory response status of patients,without significant adverse reactions,which has high clinical application safety.
关键词
急性胆囊炎/消炎利胆片/头孢哌酮舒巴坦/炎性因子Key words
Acute cholecystitis/Xiaoyan Lidan tablets/Cefoperazone sulbactam/Inflammatory factor引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据